The first of a new series of ‘sector focus’ reports examines the tax challenges facing pharmaceutical companies. By Chris Sterling, Andrew Hickman, Jonathan Bridges and Komal Dhall of KPMG, with in-house perspectives from Tim Woodthorpe and Helen Jones of GSK and Koichi Funabashi of Astellas.
.tmb-editorspic.jpg?sfvrsn=c9a7a0cc_1)
